Treating bile acid diarrhoea with liraglutide

Bile acid diarrhoea is a poorly recognised disorder that is surprisingly common but lacking in investment into new treatment options. The investigator-initiated study by Martin Kårhus and colleagues 1 Kårhus ML Brønden A Forman J et al. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial. Lancet Gastroenterol Hepatol. 2022; (published online July 19.)https://doi.org/10.1016/S2468-1253(22)00198-4 Summary Full Text Full Text PDF PubMed Scopus (8) Google Scholar in The Lancet Gastroenterology & Hepatology is therefore important, as it shows significant benefits of an unexpected drug, the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, which could be repurposed to help this large group of patients. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trialThe superiority of liraglutide compared with colesevelam in reducing stool frequency suggests consideration of liraglutide as a potential new treatment modality for bile acid diarrhoea, although larger confirmatory trials powered for superiority are warranted. Full-Text PDF